Isomorphic Labs secured a $2.1 billion Series B funding round led by Thrive Capital to scale its AI drug discovery engine and accelerate progress toward bringing programs to the clinic. The company positions its IsoDDE as a unified drug design engine rather than a software-only platform, with proceeds earmarked for continued development of the engine, pipeline advancement, and hiring across AI, engineering, drug design, and clinical development. Isomorphic’s internal pipeline is concentrated in oncology and immunology, and the company said it is progressing rapidly toward clinical translation, though it did not provide specific Phase I timelines in the reporting. It also maintains partnerships with large pharma companies including Novartis, Eli Lilly, and Johnson & Johnson. A round of this size underscores continued investor confidence in AI-first drug discovery as biopharma seeks new ways to de-risk target selection and shorten early development cycles.